Skip to main content
. 2019 Feb 9;42(6):751–768. doi: 10.1007/s40264-019-00797-3

Fig. 1.

Fig. 1

Incidence rates/100 PYs of AEs, SAEs, and infections among ustekinumab- and placebo-treated patients through up to year 1 in phase II/III studies of a psoriasis, b psoriatic arthritis, c Crohn’s disease, and d combined across all indications. PYs patient-years, AEs adverse events, SAEs serious adverse events